journal article·2024-09-09

Heparan Sulfate-Collagen Surface Multilayers Support Serum-Free Microcarrier Culture of Mesenchymal Stem Cells

Said J. Cifuentes, Natalia A. Theran-Suarez, Carolina Rivera-Crespo, Leonel Velez-Roman, Bryan Thacker, Charles Glass, Maribella Domenech

Publisher page

Abstract

The increasing cost of high-volume cultures and dependence on serum and growth factor supplementation limit the affordability of mesenchymal stromal cell (MSC) therapies. This has spurred interest in developing strategies that support adherent cell expansion while reducing raw material costs. Culture surfaces coated with sulfated glycosaminoglycans (GAGs), specifically heparan sulfate (HS), are an alternative to prolong growth factor retention in cell cultures. Unlike heparin, recombinant HS (rHS) offers strong binding affinity for multiple growth factors and extracellular matrix components, such as collagen I, without undesirable anticoagulant effects or xenobiotic health risks. The potential of rHS as a factor reservoir in MSC cultures remains underexplored. This study investigated the impact of rHS on the growth and anti-inflammatory properties of undifferentiated bone marrow MSCs in both planar and microcarrier-based cultures. It was hypothesized that rHS would enable MSC growth with minimal growth factor supplementation in a sulfation level-dependent manner. Cell culture surfaces were assembled via the layer-by-layer (LbL) method, combining alternating collagen I (COL) and rHS. These bilayers support cell adhesion and enable the incorporation of distinct sulfation levels on the culture surface. Examination of pro-mitogenic FGF and immunostimulatory IFN-γ release dynamics confirmed prolonged availability and sulfate level dependencies. Sulfated surfaces supported cell growth in low serum (2% FBS) and serum-free (SF) media at levels equivalent to standard culture conditions. Cell growth on rHS-coated surfaces in SF was comparable to that on heparin-coated surfaces and commercial surface-coated microcarriers in low serum. These growth benefits were observed in both planar and microcarrier (μCs) cultures. Additionally, rHS surfaces reduced β-galactosidase expression relative to uncoated surfaces, delaying cell senescence. Multivariate analysis of cytokines in conditioned media indicated that rHS-containing surfaces enhanced cytokine levels relative to uncoated surfaces during IFN-γ stimulation and correlated with decreased pro-inflammatory macrophage activity. Overall, utilizing highly sulfated rHS with COL reduces the need for exogenous growth factors and effectively supports MSC growth and anti-inflammatory potency on planar and microcarrier surfaces under minimal factor supplementation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Mesenchymal stem cell research · Periodontal Regeneration and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Bioengineering Graduate Program, University of Puerto Rico Mayaguez, Call Box 9000, Mayaguez, Puerto Rico 00681-9000, United States

Bioengineering Department, Moffitt Cancer Center, Tampa, Florida 32611, United States

Chemical Engineering Department, University of Puerto Rico Mayaguez, 3550 General Atomics Ct, G02-102, Mayaguez, Puerto Rico 00681-9000, United States

TEGA Therapeutics, Inc., 3550 General Atomics Ct, G02-102, San Diego, California 92121, United States

Funding

Division of Engineering Education and Centers

References (71)

Show source-provided references
1. 10.1089/scd.2011.036710.1089/scd.2011.0367 ↗
2. 10.1002/bit.2500810.1002/bit.25008 ↗
3. 10.1016/j.jcyt.2014.08.01110.1016/j.jcyt.2014.08.011 ↗
4. 10.1111/j.1365-2184.2010.00694.x10.1111/j.1365-2184.2010.00694.x ↗
5. US Food and Drug Administration · 2008
6. 10.1046/j.1365-2141.1997.902904.x10.1046/j.1365-2141.1997.902904.x ↗
7. 10.1089/ten.tec.2008.057210.1089/ten.tec.2008.0572 ↗
8. 10.1002/stem.13910.1002/stem.139 ↗
9. 10.1046/j.1537-2995.2002.00149.x10.1046/j.1537-2995.2002.00149.x ↗
10. 10.1634/stemcells.2004-033110.1634/stemcells.2004-0331 ↗
11. 10.1016/S0021-9258(18)67143-110.1016/S0021-9258(18)67143-1 ↗
12. 10.1210/endo-124-3-153910.1210/endo-124-3-1539 ↗
13. 10.1006/bbrc.2001.577710.1006/bbrc.2001.5777 ↗
14. 10.1074/jbc.M30346820010.1074/jbc.M303468200 ↗
15. 10.1089/gen.38.19.0710.1089/gen.38.19.07 ↗
16. 10.1016/j.expneurol.2004.05.00710.1016/j.expneurol.2004.05.007 ↗
17. Chen, G.; Thomson, J.; Hou, Z. Thermostable FGF-2 mutant having enhanced stability. 2014, US 8,772.460 B2.
18. Nolle, V. Fibroblast growth factor muteins with increased activity. 2019. US 10,336,799 B2.
19. 10.1371/journal.pone.016122910.1371/journal.pone.0161229 ↗
20. 10.1126/science.271.5252.111610.1126/science.271.5252.1116 ↗
21. 10.1111/j.2042-7158.1994.tb03831.x10.1111/j.2042-7158.1994.tb03831.x ↗
22. 10.1083/jcb.20060403510.1083/jcb.200604035 ↗
23. 10.1093/glycob/cwp03110.1093/glycob/cwp031 ↗
24. 10.1186/1478-811X-8-1410.1186/1478-811X-8-14 ↗
25. 10.1074/jbc.M109.09354210.1074/jbc.M109.093542 ↗
26. 10.1016/j.addr.2015.11.00210.1016/j.addr.2015.11.002 ↗
27. 10.1098/rsif.2015.058910.1098/rsif.2015.0589 ↗
28. 10.1083/jcb.125.5.117910.1083/jcb.125.5.1179 ↗
29. 10.1002/jbm.a.3708510.1002/jbm.a.37085 ↗
30. 10.1002/jbm.a.3761410.1002/jbm.a.37614 ↗
31. 10.1126/sciadv.abl602610.1126/sciadv.abl6026 ↗
32. 10.1038/182117a010.1038/182117a0 ↗
33. 10.1159/00052160910.1159/000521609 ↗
34. 10.1039/D0TB01454K10.1039/D0TB01454K ↗
35. 10.1002/biot.20210060510.1002/biot.202100605 ↗
36. 10.1007/s10616-010-9263-310.1007/s10616-010-9263-3 ↗
37. 10.1016/j.colsurfa.2018.05.05210.1016/j.colsurfa.2018.05.052 ↗
38. 10.1021/bm200519y10.1021/bm200519y ↗
39. Stuart B. H. · 200410.1002/0470011149 ↗
40. 10.1002/adfm.20180281810.1002/adfm.201802818 ↗
41. 10.1101/gad.179515.11110.1101/gad.179515.111 ↗
42. 10.1186/1756-0500-7-25410.1186/1756-0500-7-254 ↗
43. 10.1023/B:JOMG.0000023585.95430.f410.1023/B:JOMG.0000023585.95430.f4 ↗
44. 10.1111/wrr.1206510.1111/wrr.12065 ↗
45. 10.1021/bm100413w10.1021/bm100413w ↗
46. 10.1016/j.biomaterials.2011.04.03610.1016/j.biomaterials.2011.04.036 ↗
47. 10.1016/j.reth.2020.03.01310.1016/j.reth.2020.03.013 ↗
48. 10.1016/j.cytogfr.2019.05.00610.1016/j.cytogfr.2019.05.006 ↗
49. 10.1016/j.ces.2018.08.01710.1016/j.ces.2018.08.017 ↗
50. 10.1016/j.jbiomech.2009.12.02810.1016/j.jbiomech.2009.12.028 ↗
51. 10.1155/2014/31680310.1155/2014/316803 ↗
52. 10.1080/10255842.2015.105197310.1080/10255842.2015.1051973 ↗
53. 10.22203/eCM.v031a1110.22203/eCM.v031a11 ↗
54. 10.1007/s10529-011-0706-510.1007/s10529-011-0706-5 ↗
55. 10.1021/acsbiomaterials.9b0000810.1021/acsbiomaterials.9b00008 ↗
56. 10.1016/j.mtbio.2021.10019410.1016/j.mtbio.2021.100194 ↗
57. 10.1016/S1054-3589(05)53012-610.1016/S1054-3589(05)53012-6 ↗
58. 10.1002/adfm.20100246810.1002/adfm.201002468 ↗
59. 10.1007/0-306-47452-2_210.1007/0-306-47452-2_2 ↗
60. 10.1016/j.bbmt.2011.07.02310.1016/j.bbmt.2011.07.023 ↗
61. 10.3390/ijms1707116410.3390/ijms17071164 ↗
62. 10.1146/annurev-pharmtox-050120-10501810.1146/annurev-pharmtox-050120-105018 ↗
63. 10.1002/stem.122310.1002/stem.1223 ↗
64. 10.1186/s13287-018-0857-610.1186/s13287-018-0857-6 ↗
65. 10.1353/pbm.2001.003910.1353/pbm.2001.0039 ↗
66. 10.1038/cdd.2015.10710.1038/cdd.2015.107 ↗
67. 10.1016/j.matbio.2013.12.00110.1016/j.matbio.2013.12.001 ↗
68. 10.1007/978-3-642-23056-1_1010.1007/978-3-642-23056-1_10 ↗
69. 10.3390/molecules2206102510.3390/molecules22061025 ↗
70. Pinzon-Herrera, L. C. Enhancing Human Schwann Cells Reparative Behavior using Heparin/Collagen Layer-by-layer Coatings. Doctoral dissertation, University of Arkansas, 2022.
71. 10.1111/j.1474-9726.2009.00535.x10.1111/j.1474-9726.2009.00535.x ↗